Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0344307 (
analgesia
)
28,200
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Although numerous NSAIDs are available for use in the management of rheumatic disease, most of the members of this large class of drugs possess very similar characteristics. The great majority are acidic compounds. The acidity of the drugs allow distribution not only into inflamed tissues but also the kidneys and gastric mucosa. It is likely that these compounds produce anti-inflammatory
analgesia
by inhibiting prostaglandin synthesis. As a result of these similarities, NSAIDs have in general relative similar efficacy and toxicity when used in appropriate dosages. Common adverse effects include dyspepsia,
gastritis
, mucosal ulcers, interstitial nephritis and acute renal failure. Most of the adverse effects associated with the clinical use of these drugs are related to their effect on prostaglandin production. In some susceptible individuals, the inhibition of prostaglandin synthesis may result in a potentially fatal bronchospastic episode. Most clinical trials fail to consistently distinguish between NSAIDs. Patients however often develop distinct preferences for certain NSAIDs. The reason for this is still obscure but may reflect subtle pharmacological differences between these drugs. NSAIDs with short half-lives are quite effective on an 8 or 12 hourly dosage regimen. Compounds with longer half-lives may be associated with accumulation in the elderly and hence a higher risk of toxicity. The use of NSAIDs in the management of rheumatic disease should therefore be highly individualised.
...
PMID:NSAIDS--a consideration of their efficacy and toxicity. 265 71
The fact that nonsteroidal anti-inflammatory drugs (NSAIDs) damage the gastroduodenal mucosa is no longer contested. Endoscopic studies in normal volunteers after NSAID administration have failed to predict which NSAIDs would be safest when administered chronically. NSAID use has been associated with a disproportionately high frequency of upper gastrointestinal bleeding and perforation of ulcers. All of the newer NSAIDs appear to be similar in their propensity to cause mucosal damage, including peptic ulceration. On any given day, more than 10% of patients receiving NSAIDs chronically will have a gastric ulcer, a point prevalence of ulcer disease at least 5 to 10 times higher than in patients who are not taking NSAIDs. The dose-response relationship between anti-inflammatory activity and untoward events, coupled with increased use of newer more potent NSAIDs, explains, in part, the increased incidence of NSAID-associated ulcer complication of bleeding and perforation. The possible association of the increase in prevalence of Campylobacter pylori
gastritis
with aging and the apparent increase in NSAID-associated complications in the elderly is discussed. The current status of nonsteroidal drug therapy can be summarized as follows: 1) new NSAIDs are not safer than the old NSAIDs, as far as major gastrointestinal side effects are concerned, 2) NSAIDs should be avoided when
analgesia
is the main goal, 3) if NSAIDs are required, the lowest possible dose that achieves pain relief should be used, 4) newer NSAIDs available only in relatively high anti-inflammatory activity dosages should be restricted to those patients in whom high levels of anti-inflammatory activity are desired.
...
PMID:Gastroduodenal complications of chronic NSAID therapy. 304 80
The drugs most often used for pain relief in animals are the nonsteroidal antiinflammatory drugs (NSAIDS) and the opioid analgesics. The NSAIDS are effective, inexpensive, and long-acting drugs, but their degree of
analgesia
is limited by the adverse effects at high doses. The most common adverse effect from NSAIDS is
gastritis
and gastrointestinal hemorrhage and ulceration. This is most common from high doses, or from using NSAIDS not appropriate for dogs such as ibuprofen or indomethacin. The NSAIDS used in dogs include aspirin, phenylbutazone, naproxen, piroxicam, ketoprofen, and carprofen. Carprofen is a new drug with a low incidence of side effects and its popularity is increasing at a fast rate. For more acute pain, especially acute pain from surgery or trauma, opioids are frequently administered. Opioids have the advantage of higher efficacy when the dose is increased. The incidence of adverse effects is low, but side effects of sedation are common. An important disadvantage of opioids is their short duration and low oral absorption, which necessitates a frequent injection or i.v. infusion for most patients. Recent studies have established other applications for administration of opioids such as a transdermal fentanyl patch. These applications offer new possibilities for convenient administration.
...
PMID:Principles of analgesic drug therapy. 915 65
This study presents the result of the studies explaining the effects of acupuncture on various systems and symptoms. It has been determined that endomorphin-1, beta endorphin, encephalin, and serotonin levels increase in plasma and brain tissue through acupuncture application. It has been observed that the increases of endomorphin-1, beta endorphin, encephalin, serotonin, and dopamine cause
analgesia
, sedation, and recovery in motor functions. They also have immunomodulator effects on the immune system and lipolithic effects on metabolism. Because of these effects, acupuncture is used in the treatment of pain syndrome illnesses such as migraine, fibromyalgia, osteoarthritis, and trigeminal neuralgia; of gastrointestinal disorders such as disturbance at gastrointestinal motility and
gastritis
; of psychological illnesses such as depression, anxiety, and panic attack; and in rehabilitation from hemiplegia and obesity.
...
PMID:The mechanism of acupuncture and clinical applications. 1639 78
Parenteral non-steroidal anti-inflammatory drugs (NSAIDs) are useful agents in the treatment of postoperative pain and other acute traumatic painful conditions such as fractures. Clinical trials with lornoxicam, an oxicam derivative, document its efficacy as a potent analgesic with excellent anti-inflammatory properties in painful and or/inflammatory conditions including postoperative pain and arthritic conditions. However, there is no documentation of the efficacy and tolerability of intravenous lornoxicam in Indian patients with acute painful conditions such painful traumatic conditions requiring hospitalisation and parenteral analgesics. The present study was undertaken to evaluate the efficacy and tolerability of intravenous lornoxicam in Indian patients with postoperative pain or other acute painful traumatic conditions requiring hospitalisation and parenteral
analgesia
in in-office practice conditions. In this multicentric, prospective, open, non-comparative phase IV, postmarketing surveillance study patients admitted in the nursing home for either postoperative pain or painful conditions requiring hospitalisation and parenteral
analgesia
were enrolled in the study after obtaining their informed consent. Of the 161 patients fulfilling the selection criteria, 148 met the selection criteria and were included in the efficacy analysis. Patients were treated with intravenous lornoxicam 8 mg twice or three times daily as required for up to 3 days. Efficacy variables included changes in severity of pain scores compared to baseline values, onset of pain relief and overall global efficacy. Tolerability was assessed through monitoring of treatment-emergent adverse events, physical examination, assessments of vital signs, and overall global assessment of tolerability. Results indicated that within 1 hour of administration of intravenous lornoxicam, the mean scores of pain severity were reduced by 39.46% and by 6 hours, there was a further 52% reduction in the mean scores. Therapy with intravenous lornoxicam was associated with a faster onset of action with 15.4% patients reporting pain relief within 10 minutes and 55.9% patients within 10 to 30 minutes. Overall, global assessment of efficacy was rated as good to excellent in 95.3% of the patients. Therapy with intravenous lornoxicam was well tolerated with only 5 patients reporting adverse events such as headache (n=3) and
gastritis
(n=1) of mild to moderate intensity but transient. Overall, global tolerability was rated as good to excellent in 98.4% of the total cases and fair in only 1.6% of the cases. In conclusion, the results of the present study indicate that intravenous lornoxicam is a potent NSAID with an optimal efficacy/toxicity ratio and thus could be a suitable therapeutic option in the management of patients with painful traumatic conditions requiring parenteral NSAIDs and hospitalisation.
...
PMID:Lornoxicam efficacy in acute pain (LEAP) trial. 1937 Sep 57
Acute abdomen can be defined as a medical emergency in which there is sudden and severe pain in abdomen with accompanying signs and symptoms that focus on an abdominal involvement. It accounts for about 8 % of all children attending the emergency department. The goal of emergency management is to identify and treat any life-threatening medical or surgical disease condition and relief from pain. In mild cases often the cause is
gastritis
or gastroenteritis, colic, constipation, pharyngo-tonsilitis, viral syndromes or acute febrile illnesses. The common surgical causes are malrotation and Volvulus (in early infancy), intussusception, acute appendicitis, and typhoid and ischemic enteritis with perforation. Lower lobe pneumonia, diabetic ketoacidosis and acute porphyria should be considered in patients with moderate-severe pain with little localizing findings in abdomen. The approach to management in ED should include, in order of priority, a rapid cardiopulmonary assessment to ensure hemodynamic stability, focused history and examination, surgical consult and radiologic examination to exclude life threatening surgical conditions, pain relief and specific diagnosis. In a sick patient the initial steps include rapid IV access and normal saline 20 ml/kg (in the presence of shock/hypovolemia), adequate
analgesia
, nothing per oral/IV fluids, Ryle's tube aspiration and surgical consultation. An ultrasound abdomen is the first investigation in almost all cases with moderate and severe pain with localizing abdominal findings. In patients with significant abdominal trauma or features of pancreatitis, a Contrast enhanced computerized tomography (CECT) abdomen will be a better initial modality. Continuous monitoring and repeated physical examinations should be done in all cases. Specific management varies according to the specific etiology.
...
PMID:Emergency management of acute abdomen in children. 2345 44